scholarly journals Impact of Primary Site Surgery on Survival of Patients with de novo Stage IV Breast Cancer

2021 ◽  
Vol Volume 13 ◽  
pp. 319-327
Author(s):  
Zhen Huang ◽  
Qixing Tan ◽  
Qinghong Qin ◽  
Qinguo Mo ◽  
Changyuan Wei
Keyword(s):  
Breast Cancer ◽  
De Novo ◽  
Stage Iv ◽  
Primary Site ◽  
Stage Iv Breast Cancer

scholarly journals Incorporation of biologic factors for the staging of de novo stage IV breast cancer

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Zhen-Yu He ◽  
Chen-Lu Lian ◽  
Jun Wang ◽  
Jian Lei ◽  
Li Hua ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Score ◽  
Distant Metastasis ◽  
De Novo ◽  
Stage Iv ◽  
Staging System ◽  
Sensitivity Analyses ◽  
Operating Characteristics ◽  
Prognostic Analysis ◽  
Stage Iv Breast Cancer

Abstract This study aimed to investigate the prognostic value of biological factors, including histological grade, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) status in de novo stage IV breast cancer. Based on eligibility, patient data deposited between 2010 and 2014 were collected from the surveillance, epidemiology, and end results database. The receiver operating characteristics curve, Kaplan–Meier analysis, and Cox proportional hazard analysis were used for analysis. We included 8725 patients with a median 3-year breast cancer-specific survival (BCSS) of 52.6%. Higher histologic grade, HER2-negative, ER-negative, and PR-negative disease were significantly associated with lower BCSS in the multivariate prognostic analysis. A risk score staging system separated patients into four risk groups. The risk score was assigned according to a point system: 1 point for grade 3, 1 point if hormone receptor-negative, and 1 point if HER2-negative. The 3-year BCSS was 76.3%, 64.5%, 48.5%, and 23.7% in patients with 0, 1, 2, and 3 points, respectively, with a median BCSS of 72, 52, 35, and 16 months, respectively (P < 0.001). The multivariate prognostic analysis showed that the risk score staging system was an independent prognostic factor associated with BCSS. Patients with a higher risk score had a lower BCSS. Sensitivity analyses replicated similar findings after stratification according to tumor stage, nodal stage, the sites of distant metastasis, and the number of distant metastasis. In conclusion, our risk score staging system shows promise for the prognostic stratification of de novo stage IV breast cancer.

scholarly journals Locoregional therapy of the primary tumour in de novo stage IV breast cancer in 216 066 patients: A meta-analysis

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Ritika Gera ◽  
Hiba E. L. Hage Chehade ◽  
Umar Wazir ◽  
Salim Tayeh ◽  
Abdul Kasem ◽  
...  
Keyword(s):  
Breast Cancer ◽  
De Novo ◽  
Meta Analysis ◽  
Primary Tumour ◽  
Stage Iv ◽  
Locoregional Therapy ◽  
Stage Iv Breast Cancer

scholarly journals Incidence and Survival Among Young Women With Stage I–III Breast Cancer: SEER 2000–2015

2019 ◽  
Vol 3 (3) ◽  
Author(s):  
Alexandra Thomas ◽  
Anthony Rhoads ◽  
Elizabeth Pinkerton ◽  
Mary C Schroeder ◽  
Kristin M Conway ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Survival Data ◽  
De Novo ◽  
Stage Iv ◽  
Premenopausal Women ◽  
The United States ◽  
Stage I ◽  
Low Grade ◽  
High Grade ◽  
Stage Iv Breast Cancer

Abstract Background Although recent findings suggest that de novo stage IV breast cancer is increasing in premenopausal women in the United States, contemporary incidence and survival data are lacking for stage I–III cancer. Methods Women aged 20–29 (n = 3826), 30–39 (n = 34 585), and 40–49 (n = 126 552) years who were diagnosed with stage I–III breast cancer from 2000 to 2015 were identified from the Surveillance, Epidemiology, and End Results 18 registries database. Age-adjusted, average annual percentage changes in incidence and 5- and 10-year Kaplan-Meier survival curves were estimated by race and ethnicity, stage, and hormone receptor (HR) status and grade (low to well and moderately differentiated; high to poorly and undifferentiated) for each age decade. Results The average annual percentage change in incidence was positive for each age decade and was highest among women aged 20–29 years. Increased incidence was driven largely by HR+ cancer, particularly HR+ low-grade cancer in women aged 20–29 and 40–49 years. By 2015, incidence of HR+ low- and high-grade cancer each independently exceeded incidence of HR− cancer in each age decade. Survival for HR+ low- and high-grade cancer decreased with decreasing age; survival for HR− cancer was similar across age decades. Among all women aged 20–29 years, 10-year survival for HR+ high-grade cancer was lower than that for HR+ low-grade or HR− cancer. Among women aged 20–29 years with stage I cancer, 10-year survival was lowest for HR+ high-grade cancer. Conclusions HR+ breast cancer is increasing in incidence among premenopausal women, and HR+ high-grade cancer was associated with reduced survival among women aged 20–29 years. Our findings can help guide further evaluation of preventive, diagnostic, and therapeutic strategies for breast cancer among premenopausal women.

Disparities among older women with de novo stage IV breast cancer treated with trastuzumab from 1999 to 2009.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 646-646
Author(s):  
Ines Maria Vaz Duarte Luis ◽  
Nancy Lynn Keating ◽  
Nancy U. Lin ◽  
Joyce Lii ◽  
Eric P. Winer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Older Women ◽  
De Novo ◽  
Stage Iv ◽  
Stage Iv Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document